Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27161872 | 1.00 | GAA (0.48) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL27161609 | 0.90 | GAA (0.46) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL30050126 | 0.90 | GAA (0.46) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL27162286 | 0.87 | ALDH1A1 (0.61) | GAAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27162351 | 0.87 | GAA (0.48) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL30049539 | 0.87 | ALDH1A1 (0.61) | GAAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL30049402 | 0.86 | ALDH1A1 (0.49) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL27161859 | 0.86 | ALDH1A1 (0.49) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL30049839 | 0.84 | ALDH1A1 (0.49) | GAAKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL27161935 | 0.84 | ALDH1A1 (0.49) | GAAKDM4EALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | claimed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | claimed |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | disclosed |
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | GAA 3700/4885KDM4E 3959/4885ALDH1A1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.